Authors

Latest:

Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.

J. Kellogg Parsons, MD

Latest:

Dr. Parsons Discusses the Link Between Exercise and Bladder Cancer Risk

J. Kellogg Parsons, MD, associate professor of surgery (urology), University of California, San Diego, discusses modifiable lifestyle factors associated with bladder cancer.

J. Michael Dixon, MD

Latest:

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

J. Phillip Boudreaux, MD, FACS, Harvard Medical School

J. Russell Davis, MD

Latest:

Dr. Davis on Comparisons Between Robotic Surgery and Open Surgery in Lung Cancer

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.

J. Russell Hoverman, MD, PhD

Latest:

Ranking Value in Cancer Care: Analysis of a "Pathways" Approach

Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.

Jack A. Roth, MD

Latest:

Dr. Roth Compares Surgery With SBRT in Lung Cancer

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Jack Cuzick

Latest:

Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen

Jack Di Palma, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Jack West, MD, Swedish Cancer Institute

Jackie Rogers

Latest:

Plan Now for MIPS Reporting in 2018

The end of the year is always hectic for oncology practices, but 2017 is proving exceptionally busy as CMS' Quality Payment Program transitional year comes to a close.

Jacob Gersh, PhD

Latest:

Jacob Gersh Discusses the CyberKnife

Jacob Gersh, PhD, lead physicist at the Gibbs Cancer Center & Research Institute, discusses the CyberKnife.

Jacob Laubach, MD, MPP

Latest:

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Jacob Sands, MD

Jacob Sands, MD, is associate chief of the Lowe Center for Thoracic Oncology and oncology medical director of the International Patient Center at Dana-Farber Cancer Institute; as well as an assistant professor at Harvard Medical School

Latest:

Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

Jacob Sands, MD, Dana-Farber Cancer Institute

Latest:

Novel Treatment Approaches for SCLC and Future Perspectives

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Jacqueline Barrientos, MD, Zucker School of Medicine at Hofstra/Northwell

Jacqueline C. Barrientos, MD

Latest:

Noncovalent BTK Inhibitors in CLL

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, MS

Latest:

CAR T-Cell Therapies in CLL

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD

Latest:

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Jacqueline D. Barrientos, MD, MS

Latest:

Dr. Barrientos on the Challenges in CLL

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.